ClinicalTrials.gg
RecruitingNCT07733349Updated Nov 4, 2026

Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease

A Phase 1/2 interventional study of UX-DA003 in Parkinson's Disease, sponsored by Shanghai UniXell Biotechnology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Shanghai UniXell Biotechnology Co., Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
174th of 211
12 · median 47
Started
2026
with 40 others
Phase 1/2
10 of 279
5 open now
Primary completion
2029-08
later than 127 of 134 live
Registered
268th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 174th largest by planned enrollment of the 211 interventional ones that give a count, is one of 41 that started in 2026, is one of 10 in phase 1/2, reaches primary completion later than 127 of the 134 other live ones, and was the 268th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

122 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.

Read the detailed description

This study is an open-label, multicenter, two-stage, Phase I/II clinical trial. Phase I study is a single-arm, open-label, dose-escalation clinical study aimed at evaluating the safety, tolerability, and preliminary efficacy of UX-DA003 transplantation therapy for PD patients across different dosage groups, as well as determining the recommended Phase II dose (RP2D). Eligible participants include PD patients who have experienced significant decline in response to standard anti-PD treatment and have not undergone DBS surgery. The study plans to establish two dosage. A total of 12 patients are planned for enrollment. Each patient will undergo a single dose of UX-DA003 for bilateral putamenal cell transplantation.

Phase II study is a single-arm, open-label, single-dose study aimed at further evaluating the efficacy and safety of UX-DA003 for the treatment of PD patients at the RP2D dose, providing evidence for Phase III confirmatory clinical studies. The enrollment population is the same as in the clinical Phase I. This phase includes only one dose group, with the dose being the recommended dose (RP2D) determined in the Phase I stage.

The trial visit schedule includes screening period (D-30\~D-8), baseline period (D-7\~D-1), surgery and postoperative observation period (D0\~D28), and follow-up period (M3\~M24).Patients who have completed the 24-month follow-up will enter the long-term follow-up period.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • allogeneic iPSC derived mDAPs
  • Parkinson's Disease
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 30 and 75 years, regardless of gender
  • Diagnosed with Parkinson's disease conforming to relevant clinical diagnostic standards with a medical history of 5-20 years
  • Having received standard anti-PD treatment and been given optimal anti-PD treatment under the guidance of the investigator, but the efficacy has significantly declined
  • Good response to levodopa medications, the levodopa challenge test (LCT) shows that the maximum improvement rate of the UPDRS-III score exceeds 30%
  • The modified H\&Y staging (Off period) of ≥2.5 and ≤4, with total daily "off" time >2 hours
  • Stable dose of anti-Parkinson' disease drugs for at least 4 weeks prior to screening
  • Good physical condition or stable concomitant diseases

Exclusion criteria

Exclusion Criteria:

  • The subjects with atypical Parkinson's syndrome or secondary Parkinson's syndrome
  • Severe systemic diseases or functional impairments
  • Evidence of active infection or chronic infection, which may pose a risk to the subject
  • Severe concomitant central nervous system diseases or severe cognitive and psychiatric disorders
  • Subjects with a history of brain injuries, cerebral vascular malformations, hydrocephalus, brain tumors, or other brain damages as shown by previous Head CT/MRI scans, or subjects with abnormal brain imaging in the striatum or other brain regions that significantly increase surgical risks
  • Subjects who have participated in clinical trials for stem cell therapy or gene therapy for Parkinson's disease, or have participated in other interventional clinical trials within the last 3 months
  • Subjects with a history of severe allergies or reactions, known hypersensitivity to the drug or its ancillary materials, or intolerance to them
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    UX-DA003

    Drug: UX-DA003

Interventions

  • DrugUX-DA003

    UX-DA003 (Human Allogeneic iPSC-derived Midbrain Dopaminergic Progenitor cells) is used for treating patients with PD via implanting into bilateral putamina under stereotactic neurosurgery.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Within 6 months after administration

Secondary outcomes

  1. Changes in 18F-FP-CIT uptake detected by positron emission tomography (PET)

    Time frame: Within 24 months after administration

  2. Changes in MDS-UPDRS scores

    Time frame: Within 24 months after administration

  3. Changes in modified H&Y staging

    Time frame: Within 24 months after administration

  4. Changes in daily levodopa equivalent dose (LED)

    Time frame: Within 24 months after administration

  5. Changes in average daily 'off' and 'on' duration while awake

    Time frame: Within 24 months after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2029, 35 months after the start.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 35 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 29, 2026
StartActual
Sep 24, 2026was Aug 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2032
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine is now Recruiting
Nov 4, 2026
Start date
Aug 3, 2026→Sep 24, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine is now Recruiting
    Start date Aug 3, 2026→Sep 24, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07733349
Lead sponsor
Shanghai UniXell Biotechnology Co., Ltd
Collaborators
Ruijin Hospital
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 24, 2026
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2032 (estimated)
Last update
Nov 4, 2026

Study contacts

Jun Liu, MD, PhD
Contact
jly0520@hotmail.com
+86-21-64370045

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion